HeRui BioMed

What HeRui BioMed does

HeRui BioMed (苏州和锐生物科技有限公司) is a Suzhou-headquartered Chinese in vitro diagnostics (IVD) company founded in 2012 that specializes in laboratory diagnosis of digestive system diseases, primarily inflammatory bowel disease (IBD) and occult/liver disease. The company's core technology is a self-developed nano-antibody quantitative detection platform (纳米抗体精准定量技术), on which it has built what it describes as the most comprehensive IBD testing portfolio globally — 20+ testing solutions and 60+ testing services covering screening, differential diagnosis, staging, efficacy monitoring, prognosis and relapse monitoring. It holds 42 invention patents and runs a Class III IVD reagent production license, with eight registered products, 14 pending registration, 18 awaiting registration, and 16 projects in R&D.

The company's revenue model is a hybrid of (i) IVD reagent and supporting instrument sales to hospital laboratories, (ii) fee-for-service medical testing through two wholly-owned clinical laboratories in Suzhou and Changsha, and (iii) co-built technical platform services that bundle equipment, reagents, SOPs, technical training and report interpretation for hospital clients. Go-to-market is direct B2B enterprise field sales targeting Grade III (tertiary) hospitals in 14 Chinese provinces, supplemented by direct-to-consumer/patient sample acceptance via an online report query portal. The company has cultivated a clinical-academic ecosystem through joint IBD engineering research centers with Zhejiang Provincial Hospital of TCM, Beijing Military Region General Hospital, and Shanghai Jiao Tong University, and has run international technology partnerships with Israel's Tel Aviv University and Sweden's Peviva to localize cutting-edge assays for Chinese patients.

Its customer base comprises 70+ Grade III hospitals and 300+ medical institutions across 14 provinces, anchored on what it claims is China's largest IBD specimen bank with over 50,000 preserved samples. Funding history is modest: a Series 1 of approximately $456K in June 2016 (Zhejiang Collaborative Innovation North Investment Management) followed by a Series 2 of approximately $1.57M in May 2018 (HJ Capital and WisdoMont Asset Management). Headcount is 11-50 employees. The company is privately held, founder-led, with no disclosed parent, public listing, or subsequent institutional capital event after 2018.

Name

HeRui BioMed

Legal name

苏州和锐艾比迪医学检验所有限公司 (Suzhou HeRui IBD Medical Testing Laboratory Co., Ltd.)

Website

https://herui.co

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

HeRui BioMed (苏州和锐生物科技有限公司), founded 2012 in Suzhou, is a Chinese in vitro diagnostics company that develops and sells nano-antibody-based reagent kits and clinical testing services for digestive system diseases — primarily inflammatory bowel disease (IBD) and liver disease — serving 70+ Grade III hospitals and 300+ medical institutions across 14 Chinese provinces.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

akta.pro secondary industries

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), General Gastroenterology (HLAKAEAA), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

Keywords

• In vitro diagnostics
• IBD diagnostic reagents
• Digestive disease diagnostics
• Liver fibrosis testing
• Medical laboratory testing

Headquarters

HQ city

Suzhou

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Reagent Sales: Development, production, and sale of in vitro diagnostic reagents for liver injury, IBD, and other digestive system diseases, including配套检测仪器 (supporting testing instruments). Products include 8 registered reagent products and 14 pending registration.
2. Medical Testing Services: High-end clinical testing services provided through two medical testing laboratories (苏州和锐艾比迪 and 长沙和锐), offering 60+ testing services including early IBD screening, differential diagnosis, biologic drug monitoring, and liver injury detection. Services provided to hospitals and clinical institutions.
3. Co-built Technical Platform Services: Full-process technical platform design and implementation for hospitals, including equipment, reagents, SOPs, and report interpretation, plus professional technical training and ongoing support.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

HeRui BioMed develops, manufactures, and sells proprietary in vitro diagnostic (IVD) reagent kits for digestive system diseases, anchored by the IBD Five Items panel (used in inflammatory bowel disease diagnosis) and liver disease markers such as CK18-M30, CK18-M65, GP73, Chondrex (CHI3L1), and NLRP3 inflammasome. In parallel, the company operates medical testing laboratories that deliver digestive-disease diagnostic testing services to hospitals, clinics, and patients, and co-builds digestive disease specialty platforms with hospital partners using its nano-antibody quantitative detection technology.

Product overview

HeRui BioMed is a medical diagnostics company specializing in digestive system disease laboratory diagnosis technology. The company operates as a single unified platform offering both IVD reagent products and medical testing services. Core product lines include: (1) IBD diagnostic reagent kits including IBD五项, IBD新五项, and fecal biomarkers (fecal calprotectin and lactoferrin); (2) Biologic drug monitoring including infliximab drug concentration and anti-drug antibody detection; (3) Liver disease diagnostic kits including CK18-M30 and CK18-M65 series; (4) Infectious disease diagnostics including C. difficile toxin detection. The company provides over 60 testing services through its Suzhou and Changsha medical laboratories, serving 70+ tertiary hospitals across 14 provinces. They are the first domestic company with the most comprehensive IBD testing solutions internationally.

Differentiator

Problem solved

Functional benefit

Products and services

• IBD Five Items Diagnostic Reagent Kit A proprietary in vitro diagnostic reagent kit composed of five quantitative markers used by hospital clinical laboratories for the diagnosis of inflammatory bowel disease (IBD). Sold to hospital clinical labs and gastroenterology departments for routine clinical use.
• Liver Disease Diagnostic Reagent Line (CK18-M30 / CK18-M65) A suite of proprietary IVD reagents including CK18-M30 and CK18-M65 apoptosis-marker assays used by clinical laboratories for the quantitative assessment of liver fibrosis, steatohepatitis, and related chronic liver conditions. Sold to hospital labs for routine hepatology diagnostics.
• GP73 / Chondrex (CHI3L1) / NLRP3 Inflammasome Diagnostic Reagents Specialized proprietary IVD reagent assays for GP73 (liver disease), Chondrex/CHI3L1 (liver injury/inflammation), and NLRP3 inflammasome (inflammatory signaling) markers, sold to hospital clinical laboratories for targeted liver and digestive inflammatory disease diagnostics.
• Digestive System Disease Diagnostic Testing Services Clinical diagnostic testing services for digestive system diseases delivered through HeRui BioMed's affiliated medical testing laboratories, using company-developed IVD reagents and nano-antibody quantitative detection to test hospital-collected and self-collected patient samples for inflammatory bowel disease, liver fibrosis, steatohepatitis, and related conditions. Sold to referring hospitals, clinics, and individual patients.
• Co-built Digestive Disease Specialty Diagnosis and Treatment Platforms Integrated digestive-system specialty diagnosis and treatment platforms that HeRui BioMed co-builds with partner hospitals, combining the company's proprietary IVD reagents, testing capabilities, and clinical workflow expertise to provide standardized digestive-disease diagnostic services inside the partner hospital. Offered to hospital gastroenterology and hepatology departments as a packaged service.

Quantifiable outcome

• CD sensitivity 81%, UC sensitivity 50-70%, reaching international standards
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Four partnerships are on record, tiered core.

• 浙江省中医院 (Zhejiang Provincial Hospital of TCM)coreStrategic or Co-development PartnerJointly undertook the Ministry of Science and Technology 12th Five-Year Science and Technology Support Program 'Medical Device Frontier Innovation Product Development' project. Established a joint IBD in vitro diagnostic engineering technology research center. Zhejiang Provincial Hospital serves as a key clinical partner for validation and technology translation.
• 北京军区总医院 (Beijing Military Region General Hospital)coreStrategic or Co-development PartnerCo-partner in the Ministry of Science and Technology 12th Five-Year Science and Technology Support Program. Established a joint IBD in vitro diagnostic engineering technology research center. Beijing Military Region General Hospital is a key clinical partner providing validation infrastructure for IBD diagnostic products.
• 特拉维夫大学 (Tel Aviv University, Israel)coreStrategic or Co-development PartnerJointly undertook Suzhou Science and Technology Plan project 'Innovative Marker and Nano-antibody Quantitative Technology-based Diagnostic Reagent Kit R&D and Industrialization for Hepatointestinal Diseases.' Tel Aviv University contributes international technology and research expertise to the partnership.
• 上海交通大学炎症性肠病诊治中心 (Shanghai Jiao Tong University IBD Diagnosis Center)coreStrategic or Co-development PartnerEstablished a joint IBD in vitro diagnostic engineering research center with Shanghai Jiao Tong University's IBD Diagnosis Center, leveraging the university's clinical expertise and research capabilities for IBD diagnostic development.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• ALPCO Diagnostics: U.S.-based specialty IVD company focused on immunoassays for IBD (fecal calprotectin, lactoferrin) and other gastrointestinal biomarkers. Directly comparable to HeRui's IBD biomarker test menu and specialty diagnostics positioning.
• Calpro AS: Norwegian diagnostics company specializing in fecal calprotectin testing for IBD — one of the highest-profile pure-play IBD biomarker specialists globally. Directly comparable to HeRui's fecal calprotectin and IBD diagnostic franchise.
• Autobio Diagnostics: Major Chinese IVD manufacturer with broad clinical chemistry, immunoassay, and microbiology reagent portfolios. Comparable as a domestic Chinese IVD peer competing for hospital reagent contracts in the same end-market.
• Snibe (Shenzhen New Industries Biomedical Engineering): Chinese IVD manufacturer specializing in chemiluminescence immunoassay platforms and reagent kits, including specialty and infectious disease panels. Comparable as a domestic Chinese IVD reagent manufacturer competing for Chinese hospital reagent placement.
• Prometheus Laboratories (Nestlé Health Science): Specialty GI diagnostics company (acquired by Nestlé Health Science) historically known for IBD testing (IBD Serology 7, Prometheus IBD Diagnostic System). Closest international analog to HeRui's specialty IBD IVD franchise.

Broad incumbents

• Bio-Rad Laboratories: Global IVD and life science research company with a broad reagent and immunoassay portfolio including IBD and autoimmune markers. Comparable as a broad incumbent IVD player whose specialty diagnostics overlap with HeRui's reagent manufacturing base.
• Werfen (INOVA Diagnostics): Global specialty diagnostics company within the Werfen group, focused on autoimmune and specialty immunoassays. Comparable as a broader specialty IVD player whose biomarker testing menu intersects with HeRui's autoimmune liver and IBD panels.
• KingMed Diagnostics: Leading independent clinical laboratory network in China providing diagnostic testing services to hospitals and clinics. Comparable as a China-based operator of medical testing laboratories offering services to hospital clients across many provinces — directly comparable to HeRui's Suzhou and Changsha testing labs.
• ADICON Clinical Laboratories: Major Chinese independent medical laboratory network offering routine and specialty clinical testing. Comparable to HeRui's medical testing services business across multiple provinces with overlapping hospital-channel relationships.
• Mindray (Shenzhen Mindray Bio-Medical Electronics): Largest Chinese IVD and medical device manufacturer offering immunoassay instruments, reagents, and lab automation. Comparable as a broad Chinese IVD incumbent whose reagent and instrument portfolio overlaps with HeRui's IVD reagent and配套仪器 offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HeRui BioMed